Final answer:
The primary CV side effect of bevacizumab is an increased risk of arterial thromboembolic events. Bevacizumab is an anti-angiogenic medication used in cancer treatment that can cause serious cardiovascular complications.
Step-by-step explanation:
The primary cardiovascular (CV) side effect associated with bevacizumab, a medication often used in cancer treatment, is an increased risk of developing arterial thromboembolic events such as heart attacks and strokes. Bevacizumab is an anti-angiogenic agent, which means it works by inhibiting the growth of new blood vessels that feed tumors. While effective in slowing down tumor growth, it can also affect normal blood vessel behavior, leading to cardiovascular complications. Individuals receiving bevacizumab should be closely monitored for symptoms of these events, including chest pain, shortness of breath, weakness, and changes in vision or speech.
It is essential to consider the risk versus benefit when prescribing bevacizumab, and doctors usually avoid its use in patients with a history of significant cardiovascular disease.